HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Legend Biotech (LEGN.US) Offer Update - Is the Deal Really Dead?

Legend Biotech (LEGN.US) Offer Update - Some New Information About the Takeover Worth the Attention

Legend Biotech (LEGN.US) Offer Update - The Takeover Negotiations Could Reach an Impasse?

Event-Driven

<ul>
<li>Genscript announced the deconsolidation of Legend Bio. Although it may not necessarily be directly related to a potential merger, this move is beneficial for both parties from a strategic perspective.</li>
<li>Genscript is still the largest shareholder of Legend Bio, but the negative vote against Wang Ye in October indicates that there are clear divisions among major shareholders. </li>
<li>If AquaPoint votes against Wang Ye at shareholders’ meeting, it indicates that there are also divisions among co-founders. In this case, the probability of Legend Bio being sold greatly increases.</li>
</ul>


Genscript announced the deconsolidation of Legend Bio. Although it may not necessarily be directly related to a potential merger, this move is beneficial for both parties from a strategic perspective.
Genscript is still the largest shareholder of Legend Bio, but the negative vote against Wang Ye in October indicates that there are clear divisions among major shareholders. 
If AquaPoint votes against Wang Ye at shareholders’ meeting, it indicates that there are also divisions among co-founders. In this case, the probability of Legend Bio being sold greatly increases.


Legend Biotech (LEGN.US) Offer Update - Will Deconsolidation Increase the Chances of a Merger ?

Legend Biotech Corp

Legend Biotech (LEGN.US) Offer Update - Will Deconsolidation Increase the Chances of a Merger ?